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Anti-inflammatory activityAbstract The oleanolic acid (1), a natural pentacyclic triterpenoid, was quantitatively isolated
from pomace olive (Olea europaea L.) under ultra-sonication conditions (6.8 g (3.4 mg/g DW)).
Two series of oleanolic acid-1-phenyl-1H-[1,2,3]triazol-4-ylmethylester 6a–g and new oleanolic
acid-1-phenyl-1H-[1,2,3]triazol-5-ylmethylester 7a–g congeners have been designed and synthesized
in an attempt to develop potent anticancer and anti-inflammatory agents. A facile and regiospecific
synthesis of 1,2,3-triazoles catalyzed by Cu(I) (CuAAC) or Ru(II) (RuAAC) and conducted under
microwave conditions of oleanolic acid–alkyne derivative 5 with various aromatic azides 2a–g
afforded a series of 1,4- and 1,5-triazolyl derivatives, respectively. Their structures were confirmed
by using 1H NMR, 13C NMR, NOESY and HRMS analysis. Most of the compounds were
evaluated for their anticancer and anti-inflammatory activities. Oleanolic acid 1 exhibited promising
anticancer activity against murine breast (EMT-6) and human colon (SW480) cancer cells. Itsticancer
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and anti-inflammatory activities of oleanolicderivatives 6b and 6c (1,4-regioisomers) and 7b (1,5-regioisomer) were found to be anti-cancer
agents. On the other hand, only 6b displays anti-inflammatory activity.
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A review of the literature showed that some triterpenes and their
derivatives have been associated with various pharmacological activi-
ties. They have shown good antitumoral (Schwarz and Csuk, 2010),
antioxidant (Chiung et al., 2010), anti-inflammatory (Bednarczyk-
Cwynar et al., 2012), antiviral (Grishko et al., 2014), antibacterial
and antifungal (Chouaı¨b et al., 2015; Hichri et al., 2003) activities.
Oleanolic acid (3b-hydroxyolean-12-en-28-oic acid, 1) is a natural
pentacyclic triterpenoid compound (Fig. 1), widely distributed
throughout the vegetable kingdom (Guo et al., 2015; Liu, 2005). This
compound and some of its derivatives have been reported to possess
various biological activities such as anticancer (Srivastava et al.,
2010), gastroprotective (Sa´nchez et al., 2006), anti-Alzheimer
(Abdalla et al., 2012), antidiabetic (Chen et al., 2006), hepatoprotective
(Yim et al., 2001) and many other important activities. Thus all the
pharmacological properties of oleanolic acid were reviewed by Liu
(1995), who mentioned also its hepatoprotective, anti-neoplastic and
anti-hyperlipidemic properties and emphasized its low toxicity.
Similarly, oleanolic acid has been marketed in China as an oral drug
for human liver disorders (Liu, 2005).
On the other hand, triazoles, an important class of N-heterocycles,
are employed in many pharmaceutical products (Farajzadeh and
Khoshmaram, 2013). In particular, 1,2,3-triazoles are of great impor-
tance in medicinal chemistry because they can act as pharmacophores
and linkers between two or more substances of interest in molecular
hybridization approaches (Agalave et al., 2011). 1,2,3-Triazoles are
among heterocyclic compounds that attract the attention of organic
chemists (Singh et al., 2010) due to their broad spectrum of applica-
tions in biochemical, medicinal chemistry and material sciences.
Several of these triazoles are drugs and have a wide range of biological
activities such as anti-HIV (Kirschberg et al., 2008), antiviral (Aufort
et al., 2008), cytotoxic (Kamal et al., 2008) and antibacterial (Wang
et al., 2010) effects. Rashid et al. (2013) suggest that ursolic acid–tria-
zolyl derivatives show an anticancer activity against a panel of human
cancer cell lines including A-549 (lung), MCF-7 (breast), HCT-116
(colon), THP-1 (leukemia) and a normal epithelial cell line (FR-2)
using sulforhodamine-B assay. Most of these compounds exhibited
better anticancer activity against all the tested cancer cell lines
compared to positive controls, 4,5-fluorouracil and mitomycin-C.
According to previous reports, it has been observed that keeping polar
substituents at the C-28 position of the triterpene skeleton enhanced its
anti-tumor potential against BGC-823 cell lines (Bai et al., 2011).
Recently, Wei et al. (2015) suggest that the incorporation of a
1,2,3-triazole moiety at C-28 position of oleanolic acid 1 was useful
to improve its cell proliferation inhibition against human cancer cell
lines.OH
O
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of oleanolic acid 1.
. et al., Regiospecific synthesis by copp
acid triazole derivatives. Arabian JournThe 1,3-dipolar cycloaddition is considered the most important and
versatile synthetic route for a wide range of 1,2,3-triazoles and triazo-
lines. The conventional synthesis of 1,2,3-triazoles relies on the Huis-
gen [3 + 2] cycloaddition between alkynes and organic azides usually
provides a mixture of 1,4- and 1,5-disubstituted regioisomers (Norris
et al., 1996; Talekar and Wightman, 1997). In general, the attempts
to separate these regioisomers by chromatography, with some excep-
tions, were not successful. The growing use of catalyzed azide–alkyne
cycloaddition named the ‘‘click” reaction, allowing the easy access to
regiospecific 1,2,3-triazoles, motivated their use in the drug discovery
field (Giffin et al., 2008). In view of the preceding literature data, we
were encouraged to synthesize oleanolic acid-(C-28)triazolyl deriva-
tives as a contribution to develop more effective therapeutic agents
by employing click chemistry protocol. Click chemistry enables a mod-
ular approach to generate these novel pharmacophores utilizing a col-
lection of reliable chemical reactions. The Huisgen 1,3-dipolar
cycloaddition of alkynes and azides (AAC) has appeared as a powerful
linking reaction to give substituted-1,2,3-triazoles. This reaction when
catalyzed with Copper (I) (CuAAC) leads exclusively to the
1,4-regioisomer (Kumar et al., 2009). On the other hand, the
ruthenium-catalyzed version of the reaction (RuAAC), affords mainly
the 1,5-regioisomer (Takasu et al., 2010).
We report herein the synthesis of 1,4- and new 1,5-disubstituted-
1,2,3-triazole derivatives from oleanolic acid 1 (Fig. 1) isolated from
pomace olive (Olea europaea L.) cultivar: Chemlali, under ultra-
sonication conditions (6.8 g (3.4 mg/g DW)) (Chouaı¨b et al., 2015).
They are prepared via well established Cu(I)-catalyzed azide–alkyne
(CuAAC) and Ru(II)-catalyzed azide–alkyne (RuAAC) cycloadditions
which were conducted for the first time under microwave and solvent
free conditions. Oleanolic acid 1 and most obtained derivatives were
evaluated for their anticancer and anti-inflammatory activities in vitro.
2. Results and discussion
The precursors 2a–g were synthesized from the appropriate
anilines using a two-step procedure by diazotization with
sodium nitrite in acidic conditions followed by displacement
with sodium azide. The desired aromatic azides 2a–g were
obtained in yields ranging from 85% to 98%. On the other
hand, compound 1 was subjected to oxidation using Jones
reagent at 0 C that resulted in the formation of C-3 oxidized
derivative 3 in quantitative yield (94%). The propargylation of
the carboxyl group at C-28 in dry DMF using NaH as catalyst
provided the propargylated ester 4 in excellent yield (98%).
The 3-oxo group of Compound 4 was selectively reduced to
C-3 hydroxyl group with sodium borohydride under micro-
wave irradiation (250 W, 3 min), to obtain the dipolarophile
5 in 99% yield (Scheme 1).
Although the Cu(I)-catalyzed Huisgen 1,3-dipolar cycliza-
tion usually proceeds in high yields, it has been reported to
be highly dependent on the substrate and reaction conditions.
Using phenylazide (2a, R = H) as a model azide, the most
suitable conditions to carry out the cyclization with alkyne 5
were explored. The use of 2 equiv of phenylazide is here neces-
sary because of its possible dimerization into secondary amine
(Lange et al., 1998; An et al., 2004). The most relevant results
of this study are shown in Table 1.er- and ruthenium-catalyzed azide–alkyne 1,3-dipolar cycloaddition, anticancer
al of Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2015.12.013
Scheme 1 Synthesis of the 1,4- and 1,5-triazolyl (6a–g, 7a–g) derivatives. Reagents and conditions: (a) Jone’s oxidation (CrO3,
H2SO4/acetone), 0 C, 94%, (b) propargyl bromide, NaH, dry DMF, rt, 98%, (c) NaBH4, CH3OH/THF, Microwave (250 W, 3 min),
99%, (d) Cuprous iodide (CuI), Et3N, solvent free, Microwave (200 W, 2–4 min), 87–98%, (e) [Cp
*RuCl(PPh3)2], DMF, Microwave
(250 W, 3–6 min), 84–96%.
Oleanolic acid triazole derivatives 3As shown in Table 1 0.5 equiv of CuI under microwave and
solvent free conditions in the presence of triethylamine as a
base (1 equiv. referred to the starting alkyne) was essential to
obtain the higher yield of the desired 1,2,3-triazole in minimum
reaction time (entry 5). Interestingly, a further increase in the
amount of CuI did not improve the yield (entry 6). However,
the excess of Cu(I) probably caused a diminution in the perfor-
mance due to the deposition of copper species on the dipole
and the low solubility of cuprous iodide in triethylamine.
The optimal condition (Table 1, entry 5) found was applied
in a regiospecific approach using Huisgen 1,3-dipolar cycload-
dition reaction (CuAAC) of the alkyne 5 with various aromatic
azides 2a–g in the presence of cuprous iodide (CuI) and Et3N
resulting into the formation of regiospecific 1,4-substituted-
triazolyl derivatives 6a–g in excellent yields (Scheme 1).
All the reactions were carried under microwave irradiation
(200 W) completed within 2–4 min. The desired compounds
6a–g were obtained in yields ranging from 87% to 98% under
microwave and solvent free conditions. This method compared
to that cited in the literature (Wei et al., 2015) for the prepara-
tion of the same compounds has the advantage of being simple
and the products can be obtained from the reaction mixture by
simple extraction.
The structure of the 1,4-substituted triazole regioisomers
were evidenced by their spectral data. The 1H NMR spectraPlease cite this article in press as: Chouaı¨b, K. et al., Regiospecific synthesis by copp
and anti-inflammatory activities of oleanolic acid triazole derivatives. Arabian Journof compounds 6a–g showed a singlet at dH 7.96–8.02 attributa-
ble to the proton H-5 of the triazole moiety and signals at the
aromatic region (dH 7.00–7.70) relative to the aromatic protons
introduced by the azides used. These structures were further
supported by 13C and DEPT NMR spectra, which showed
all the expected carbon signals corresponding to oleanolic
acid–triazolyl derivatives, essentially the aromatic carbons res-
onating at dC 114.2–159.3 introduced by the azides used.
The resulting 1,4-regioisomers were evidenced from the
NOE between H-5triazole/Hmethylene and H-5triazole/Harom, and
the absence of NOE between Hmethylene/Harom, and such
regiospecificity agrees with that cited in the literature
(Kumar et al., 2009; Li et al., 2014). High Resolution Mass
Spectrometry (HRMS) data of all the formed derivatives were
also in agreement with the proposed structures.
On the other hand, we turned our attention to the ruthe-
nium–catalyzed version of the reaction (RuAAC), which is less
extensively described and led mainly to 1,5-regioisomers
(Boren et al., 2008). Generally, the common approaches to
1,5-regioisomers were based on Grignard reagents (Krasinski
et al., 2004), or 1-trimethylsilylalkynes (Coats et al., 2005).
Microwave heating allows a significant acceleration of the
reaction from 8 h to 2 min (Table 1). Working under micro-
wave irradiation in DMF, we first investigated the optimal
conditions for the cycloaddition of alkyne 5 and phenylazideer- and ruthenium-catalyzed azide–alkyne 1,3-dipolar cycloaddition, anticancer
al of Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2015.12.013
Table 1 Optimization of Cu(I)-catalyzed 1,3-dipolar cyclization for the synthesis of 1,2,3-triazoles.a
Entry CuI (equiv)b Solvent Et3N (equiv)
b Condition Time (h) Yield (%)d
1 0.3 DMF 0.1 rt 8 40
2 0.1 DMF 0 rt 8 Traces
3 0.5 DMF 1 110 C 8 85
4 0.5 DMF/H2O (1:1) 1 Microwavec 0.1 90
5 0.5 Solvent free 1 Microwavec 0.033 92
6 2 Solvent free 1 Microwavec 0.1 50
Bold in entry highlights the optimal reaction conditions.
a Alkyne 5 (2 mmol) and two equivalents of phenylazide 2a.
b Referred to the starting alkyne 5.
c The reaction was performed at 200 W.
d Isolated yield after column chromatography (EP-EtOAc), based on the starting dipolarophile 5.
Table 2 Optimization of RuAAC under microwave conditions (250 W).a
Entry Catalyst (mol%)b Solvent Irradiation time (min) Conversion (%)
1 1 DMF 10 50
2 3 DMF 10 80
3 5 DMF 4 100
4 5 Solvent free 10 No reaction
Bold in entry highlights the optimal reaction conditions.
a Alkyne 5 (2 mmol) and two equivalents of phenylazide 2a.
b Referred to the starting alkyne.
4 K. Chouaı¨b et al.2a using different concentrations of the catalyst Cp*RuCl
(PPh3)2 (Table 2).
The total conversion of oleanolic acid–alkyne derivative 5
was obtained after only 4 min of reaction with 5% catalyst
(entry 3). For lower catalyst loading, conversion was not com-
plete, even after 10 min reaction (Table 2, entries 1 and 2).
Moreover, when we worked under solvent free conditions,
there was no reaction (entry 4).
With these optimized conditions in hand, the dipolarophile
5 was reacted with various aromatic azides and 5 mol%
Cp*RuCl(PPh3)2 catalyst. All the reactions were performed
under microwave conditions in DMF and completed within
3–6 min. The desired new compounds 7a–g were obtained in
yields ranging from 84% to 96% (Scheme 1).
The reaction was conducted with complete regiospecificity
and most of the yields remained good for the whole syntheticPlease cite this article in press as: Chouaı¨b, K. et al., Regiospecific synthesis by copp
and anti-inflammatory activities of oleanolic acid triazole derivatives. Arabian Journsequence. The structure of the prepared compounds (7a–g) was
established on the basis of their analytical data.
In addition of the signals corresponding to the protons
introduced by oleanolic acid–alkyne 5, new signals related to
the azides used were observed in 1H NMR spectra. Examina-
tion at 300 MHz showed in particular a singlet at dH
7.82–8.17 (H-4 of the triazole ring) and also other signals at
dH 7.05–7.93 (aromatic protons). The
13C NMR spectra con-
firmed the above spectral data by the observation of new sig-
nals at dC 114.2–160.1 relative to the aromatic carbons and
the triazoles formed.
The 1,5-regiochemistry thus adopted was confirmed by
NOESY spectra showing the NOE between H-4triazole/
Hmethylene and Hmethylene/Harom, and the absence of NOE
between H-4triazole/Harom, and such observation was in agree-
ment with the proposed structures and with that indicated iner- and ruthenium-catalyzed azide–alkyne 1,3-dipolar cycloaddition, anticancer
al of Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2015.12.013
Table 3 Effect of natural pentacyclic triterpenoid (oleanolic
acid 1) and the synthesized triazoles on viability of EMT-6 and
SW480 cell lines.
Tissue Breast Colon
Cell line EMT-6 SW480
Conc. (lM) Viability (% /Control)
DMSO 0.33% (Control) 100 ± 2 100 ± 2
Doxorubicin 10 6 ± 0 25 ± 1
Etoposide 10 41 ± 2 70 ± 5
5-Fluorouracil 10 26 ± 1 92 ± 2
Methotrexate 10 14 ± 0 68 ± 0
Entry Code
1 1(OA) 100 7 ± 0 13 ± 1
30 97 ± 2 121 ± 2
10 94 ± 0 114 ± 6
2 6b 100 46 ± 4 66 ± 4
30 81 ± 6 93 ± 0
10 113 ± 0 100 ± 0
3 6c 100 42 ± 4 15 ± 0
30 66 ± 5 49 ± 0
10 97 ± 2 91 ± 5
4 6e 100 78 ± 8 108 ± 5
30 112 ± 1 133 ± 2
10 107 ± 0 120 ± 6
5 6f 100 102 ± 1 112 ± 1
30 109 ± 1 106 ± 1
10 106 ± 0 110 ± 5
6 6g 100 106 ± 2 104 ± 4
30 101 ± 0 104 ± 2
10 100 ± 1 106 ± 6
7 7b 100 41 ± 2 66 ± 0
30 77 ± 1 85 ± 4
10 103 ± 2 113 ± 9
8 7c 100 94 ± 3 102 ± 0
30 104 ± 3 121 ± 4
10 114 ± 1 120 ± 1
9 7e 100 74 ± 3 105 ± 0
30 95 ± 0 107 ± 1
10 96 ± 4 101 ± 1
10 7f 100 60 ± 1 80 ± 1
30 92 ± 0 107 ± 3
10 97 ± 0 117 ± 4
Table 4 Half maximal inhibitory concentration (IC50) of
natural pentacyclic triterpenoid (Oleanolic acid 1) and the
synthesized triazoles against two tumor cell lines.
IC50 (lM)
Tissue Breast Colon
Cell line EMT-6 SW480
Anticancer drug
Doxorubicin 5.3 ± 0.1 6.8 ± 0.6
Etoposide 8.5 ± 1.0 27.8 ± 2.6
5-Fluorouracil 6.8 ± 0.6 >40
Methotrexate 5.8 ± 0.2 >40
Entry Code
1 1(OA) 66.6 ± 0.7 76.0 ± 3.0
2 6b 91.8 ± 3.3 >100
3 6c 76.0 ± 3.7 29.6 ± 1.7
4 6e >100 >100
5 6f >100 >100
6 6g >100 >100
7 7b 82.8 ± 1.7 >100
8 7c 94 ± 3 >100
9 7e 74 ± 3 >100
10 7f 60 ± 1 >100
Oleanolic acid triazole derivatives 5the literature (Takasu et al., 2010). The HRMS data of the
formed compounds 7a–g were in concordance with the estab-
lished structures.
3. Anticancer activity
The cytotoxic activity of oleanolic acid 1 and most of its
triazole derivatives were studied using cultured murine
EMT-6 (Breast) and human SW480 (colon) cancer cell lines.
Doxorubicin, etoposide, 5-fluorouracil and methotrexate
(10 lM) were used as anticancer references in this study.
Compounds 6b (4-OCH3) and 6c (4-Cl) (1,4-regioisomers)
and 7b (4-OCH3) (1,5-regioisomer) were found to be the most
promising. From the percentage viability and IC50 dataPlease cite this article in press as: Chouaı¨b, K. et al., Regiospecific synthesis by copp
and anti-inflammatory activities of oleanolic acid triazole derivatives. Arabian Journ(Tables 3 and 4) and compared to most of its derivatives,
oleanolic acid 1 displayed the highest anticancer activity,
exhibiting potent anti-proliferative activity toward breast
(EMT-6) (Viability (%/Control) = 7% (100 lM);
IC50 = 66.6 ± 0.7 lM) and colon (SW480) (Viability (%/
Control) = 13% (100 lM); IC50 = 76.0 ± 3.0 lM) cancer
cells. The anticancer activity of oleanolic acid 1 disappeared
at lower concentrations (30 and 10 lM). The results given in
Tables 3 and 4, show that the junction of oleanolic acid 1 to
triazole according to the two regiochemistry approaches
(1,4- and 1,5-) through the linker methylene did not improve
its anticancer activity.
For the 1,4-regioisomers, compounds 6b and 6c exhibited
the highest anticancer activity against breast cancer cells
(IC50 = 91.8 ± 3.3 and 76.0 ± 3.7 lM, respectively). Toward
colon cell lines, only 6c displayed a remarkable effect
(IC50 = 29.6 ± 1.7 lM), and it was found more than twice
as active as oleanolic acid 1 (IC50 = 76.0 ± 3.0 lM). The pos-
itive mesomeric effect (+M) of the methoxy group in 6b and
chlorine atom in 6cmay explain their activity compared to that
of the rest of analogues from the same series. In the contrary,
in the case of compounds 6e, 6f and 6g, the presence of 4-NO2–
C6H4, 3-CH3–C6H4 and naphthyl, respectively attached to
their triazole moieties appears to reduce considerably the anti-
cancer activity against the two cancer cell lines used.
For the 1,5-regioisomers, only 7f, bearing a 3-CH3–C6H4 in
its triazole moiety, was found to be most active against Breast
(EMT-6) cells (Viability (%/Control) = 60 ± 1% (100 lM);
IC50 = 60 ± 1 lM) followed by 7e (4-NO2) (Viability
(%/Control) = 74 ± 3% (100 lM); IC50 = 74 ± 3 lM).
Compound 7b (4-OCH3–C6H4) and 7c (4-Cl–C6H4) displayed
less activity than 7f and 7e against the same cell line
((IC50 = 82.8 ± 1.7 and 94 ± 3 lM, respectively).
These results showed clearly the contribution of the nature
of the aromatic system attached to the triazole ring in this
activity.er- and ruthenium-catalyzed azide–alkyne 1,3-dipolar cycloaddition, anticancer
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Table 5 Effect of natural pentacyclic triterpenoid (oleanolic acid 1) and the synthesized triazoles on viability
and inflammatory cytokine (IL-1b) production in LPS-stimulated PBMCs.
Conc. (lM) % PBMCs viability (/Control) % IL-1b production (/Control)
DMSO 0.33%+ LPS (Control) 100 ± 4 100 ± 2
ZVAD+ LPS 5 110 ± 4 42 ± 2
DEXA+ LPS 1 81 ± 7 32 ± 2
PRED+ LPS 70 67 ± 8 43 ± 4
Entry Code
1 1(OA) 100 73 ± 7 88 ± 3
30 73 ± 13 Nda
2 6b 100 83 ± 3 71 ± 15
30 61 ± 4 Nd
3 6c 100 56 ± 4 88 ± 1
30 47 ± 3 Nd
4 6e 100 86 ± 10 95 ± 4
30 81 ± 9 Nd
5 6f 100 80 ± 2 88 ± 3
30 61 ± 7 Nd
6 6g 100 89 ± 6 88 ± 4
30 62 ± 9 Nd
7 7b 100 59 ± 8 Nd
30 53 ± 1 83 ± 4
8 7c 100 57 ± 20 Nd
30 66 ± 2 89 ± 1
9 7e 100 56 ± 10 Nd
30 62 ± 3 104 ± 4
10 7f 100 66 ± 2 79 ± 2
30 80 ± 7 Nd
a Nd = not determined.
6 K. Chouaı¨b et al.All compounds 7 tested did not exhibit any activity toward
the used cancer cell lines (IC50 > 100 lM) toward (SW480)
colon cancer cell lines.
The results obtained show that the difference in activity of
the regioisomers 6 (1,4-) and 7 (1,5-) is undoubtedly due to
both the regiochemistry and the nature of the substituent
borne by the aromatic ring attached to the triazole.4. Anti-inflammatory activity
The anti-inflammatory activity of the tested compounds was
studied using LPS-stimulated human peripheral blood
mononuclear cells (PBMCs). Three anti-inflammatory refer-
ences were tested in the same conditions: ZVAD (5 lM), dex-
amethasone (DEXA, 1 lM) and prednisolone (PRED,
70 lM). Secretion IL-1b was measured only in the culture
supernatants of PBMCs treated with compounds that showed
no or low toxicity, using a sandwich enzyme-linked
immunosorbent assay (ELISA) method (eBioscience, San
Diego, USA), according to manufacturer instructions.
The anti-inflammatory results (Table 4) revealed that the
synthesized compounds showed variable degrees of % IL-1b
production. This finding showed that the introduction of the
1,4- and 1,5-triazole moieties in compound 1 did not consider-
ably improve its anti-inflammatory activity. In the series of
1,4-regioisomers, compound 6b was found to be relatively
the most active (% IL-1b production = 71 ± 15; 100 lM).
The significant positive mesomeric effect (+M) of the methoxy
group in para position of the aromatic ring attached to thePlease cite this article in press as: Chouaı¨b, K. et al., Regiospecific synthesis by copp
and anti-inflammatory activities of oleanolic acid triazole derivatives. Arabian Journtriazole moiety in compound 6b compared to that exerted by
the chlorine atom in compound 6c and by the methyl group
in compound 6f at the same position may explain the differ-
ence in activity between these three derivatives. On the other
hand, it has been found that compounds 6e and 6g both bear-
ing a group with a negative mesomeric effect (M) (4(NO2–
C6H4) and naphtyl, respectively) did not exhibit any activity.
On the other hand, the results showed that only 7f (3-CH3;
1,5-regioisomer) (% IL-1b production = 79 ± 2; 100 lM)
exhibited a slightly higher anti-inflammatory activity than
oleanolic acid 1 (% IL-1b production = 88 ± 3; 100 lM).
Compounds 7b, 7c and 7e were found to be not anti-
inflammatory and the triazole system in its 1,5-
regiochemistry has not improved remarkably the activity of
oleanolic acid 1 (see Table 5).
5. Conclusion
In summary, oleanolic acid 1 was quantitatively isolated from pomace
olive (O. europaea L.) cultivar: Chemlali (6.8 g (3.4 mg/g DW)) under
ultra-sonication conditions. On the other hand, we used the Copper
(I) iodide catalytic system for CuAAC and the Cp*RuCl(PPh3)2 for
RuAAC under microwave conditions to reach hitherto new natural
oleanolic acid derivatives bearing 1,4 and 1,5-disubstituted triazole,
respectively. The cooperative effect of the catalyst and the microwave
activation afforded the desired compounds in a few minutes in high
yields. This effective approach allows an easy access to a series of
1,4-regioisomers under CuAAC and 1,5-disubstituted-triazolo deriva-
tives under RuAAC. Oleanolic acid 1 and most of the prepared deriva-
tives were evaluated for the anticancer and anti-inflammatory
activities. Oleanolic acid 1 and compounds 6c (4-Cl; 1,4-regioisomer)er- and ruthenium-catalyzed azide–alkyne 1,3-dipolar cycloaddition, anticancer
al of Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2015.12.013
Oleanolic acid triazole derivatives 7and 7e (4-NO2; 1,5-regioisomer) showed the highest anticancer activity
against breast (EMT-6) and 6c was found more than twice as active as
oleanolic acid 1 toward colon (SW480) cancer cells. In this context, the
regiochemistry and the mesomeric effect appear involved in this activ-
ity. On the other hand, 6b (4-OCH3; 1,4-regioisomer) and 7f (3-CH3;
1,5-regioisomer) showed a slightly higher anti-inflammatory activity
than oleanolic acid 1.
6. Experimental section
Solvents were purified and dried using standard methods.
Melting points were determined on a Bu¨chi 510 apparatus
using capillary tubes. Commercial TLC plates (Silica gel 60,
F254, sds) were used to monitor the progress of the reaction.
Column chromatography was performed with silica gel 60
(particle size 40–63 lm, sds). HRMS spectra were acquired
with an ESI-TOF (LCT Premier XE, Waters) using the reflec-
tron mode. Leucine-enkephaline peptide was employed as a
lockmass for the LockSpray. 1H (300 MHz) and 13C
(75 MHz) NMR spectra were recorded on a Bruker AM-300
spectrometer, using CDCl3 and CD3OD as solvents. The
microwave was a Biotage AB Initiator EXP EU with a maxi-
mum power of 800 W (2450 MHz). The chemical shifts (d) are
reported in ppm relative to the residual non-deuterated solvent
as internal standard and coupling constants were measured in
Hz.
6.1. General procedure for preparation of azides 2a–g
To a suspension of the appropriate anilines in a 1:1:4 mix-
ture of H2O/HCl/ice (100 mL) was added 1.2 equiv of
sodium nitrite (NaNO2), while keeping the temperature
below 0 C. After being stirred at room temperature for
30 min, 2 equiv. of sodium azide (previously dissolved in
water) was added in small portions. The mixture was stirred
at room temperature for 2 h, poured into water, and
extracted with chloroform. The organic phase was dried over
Na2SO4, and the solvent was evaporated to give the desired
dipoles 2a–g, which were used directly in the 1,3-dipolar
cycloaddition reactions.6.2. Synthesis of 3-oxo-olean-12-en-28-oic acid (3)
To a solution of 1 (2.4 g, 5.2 mmol) in acetone (30 mL) at 0 C,
5 drops of Jones reagent were added and reaction mixture was
stirred at room temperature. Reaction was monitored by TLC
till its completion in around 3 h. After quenching the reaction
with cold water, crude product was extracted with ethyl acetate
(3  50 mL). Organic layer was dried over sodium sulfate and
purified through column chromatography to give pure 3-oxo-
olean-12-en-28-oic acid (3) (2.22 g, 94% yield). White solid;
mp: 287–289 C; 1H NMR (300 MHz, CDCl3): d 5.31 (1H, t,
J= 3.1 Hz), 2.88 (1H, dd, J= 6.7; 4.2 Hz), 2.56 (1H, m),
2.40 (1H, m), 2.05–1.92 (4H, m), 1.78–1.60 (6H, m), 1.48
(2H, m), 1.42 (2H, m), 1.35–1.29 (6H, m), 1.19 (3H, s), 1.05
(3H, s), 1.16 (3H, s), 1.10 (3H, s), 0.95 (3H, s), 0.88 (3H, s),
0.83 (3H, s); 13C NMR (75 MHz, CDCl3): d 217.1, 183.4,
143.1, 121.9, 54.8, 46.9, 46.3, 46.0, 45.8, 41.2, 40.5, 38.8,
38.6, 36.3, 33.6, 33.3, 32.5, 31.9, 31.6, 30.1, 29.1, 27.2, 25.9,
25.3, 23.0, 22.9, 22.4, 20.9, 19.0, 16.5; HRMS (ESI): calcd.
for (C30H45O3)
 [M–H] 453,3369, found 453,3390.Please cite this article in press as: Chouaı¨b, K. et al., Regiospecific synthesis by copp
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To a solution of 3 (2.2 g, 4.8 mmol) in dry DMF, sodium
hydride (230 mg, 9.6 mmol) and propargyl bromide (1.4 g,
9.6 mmol) were added and the reaction mixture was stirred
at room temperature for 2 h. Reaction was monitored by
TLC and the crude product was subjected to column chro-
matography to give pure prop-2-yn-1-yl-3-oxo-olean-12-en-28-
oate (4) (2.31 g, 98% yield). White solid; mp: 293–294 C; 1H
NMR (300 MHz, CDCl3): d 5.25 (1H, s), 4.60 (1H, dd,
J= 15.6; 2.1 Hz), 4.51 (1H, dd, J= 15.3; 2.4 Hz), 2.81 (1H,
dd, J= 7.8; 4.5 Hz), 2.34 (1H, t, J= 2.4 Hz), 1.92 (2H, m),
1.79–1.70 (6H, m), 1.85 (4H, m), 1.74 (2H, m), 1.56 (4H, m),
1.47–1.33 (4H, m), 1.17 (3H, s), 1.08 (3H, s), 1.05 (3H, s),
1.01 (3H, s), 0.89 (3H, s), 0.78 (3H, s), 0.73 (3H, s); 13C
NMR (75 MHz, CDCl3): d 216.8, 176.3, 142.8, 122.4, 77.7,
73.6, 54.8, 51.2, 47.2, 46.3, 45.4, 41.2, 40.9, 38.8, 38.3, 37.6,
33.5, 33.4, 32.5, 32.2, 31.7, 30.3, 29.1, 27.8, 27.1, 26.8, 25.3,
23.2, 22.9, 22.4, 17.9, 16.8, 15.5; HRMS (ESI): calcd. for
(C33H47O3)
 [MH] 491,3525, found 491,3561.
6.4. Synthesis of alkyne (5)
Compound 4 (2.16 g, 4.4 mmol) was dissolved in methanol and
THF mixture (20 mL, 1:1) and (0.16 g, 4.4 mmol) of sodium
borohydride was added. The reaction mixture was subjected
to microwave irradiations at 250 W for 3 min. After reaction
completion, the solvent was removed in vacuo and the residue
was diluted with water (100 mL). The mixture was acidified
with HCl aqueous solution (1 M) and extracted with ethyl
acetate (3  50 mL). The combined organic layer was dried
over anhydrous sodium sulfate and evaporated to dryness.
The residue was chromatographed over silica gel and eluted
with petroleum ether:ethyl acetate (2:1) to yield prop-2-yn-1-
yl-(3b)-3-hydroxyolean-12-en-28-oate (5) (2.15 g, 99% yield).
White solid; mp: 290–291 C; 1H NMR (300 MHz, CDCl3):
d 5.23 (1H, s), 4.61 (1H, dd, J= 15.3; 2.1 Hz), 4.49 (1H, dd,
J= 15.3; 2.4 Hz), 3.15 (1H, dd, J= 10.2; 4.5 Hz), 2.82 (1H,
dd, J= 7.8; 4.2 Hz), 2.34 (1H, t, J= 2.4 Hz), 1.93–1.82 (4H,
m), 1.64–1.49 (10H, m), 1.46–1.34 (8H, m), 1.17 (3H, s), 1.08
(3H, s), 1.05 (3H, s), 1.01 (3H, s), 0.89 (3H, s), 0.78 (3H, s),
0.73 (3H, s); 13C NMR (75 MHz, CDCl3): d 176.3, 142.9,
122.1, 78.5, 77.6, 73.8, 54.7, 51.1, 47.1, 46.3, 45.3, 41.2, 40.8,
38.9, 38.2, 37.9, 36.5, 33.3, 32.5, 32.2, 31.7, 30.1, 27.6, 27.2,
26.7, 25.3, 23.1, 22.9, 22.5, 17.8, 16.6, 15.0, 14.8; HRMS
(ESI+): calcd. for (C33H51O3)
+ [M+H]+ 495,3838, found
495,3841.
6.5. General procedure for the synthesis of compounds 6a–g:
Cu-catalyzed azide–alkyne cycloaddition
Under solvent free conditions 0.1 g (0.2 mmol) of dipo-
larophile 5, Copper(I) iodide (0.5 equiv) and triethylamine (1
equiv) were added at room temperature. To this mixture, aryl
azide (0.4 mmol) was added and the reaction mixture was
subjected to microwave irradiations at 200 W completed
within 2–4 min. The crude mixture was extracted with EtOAc
(3  25 mL) and the combined organic layer was dried over
sodium sulfate, concentrated under reduced pressure and puri-
fied through a column chromatography or recrystallization, to
give pure 6a–g in 86–98% yields.er- and ruthenium-catalyzed azide–alkyne 1,3-dipolar cycloaddition, anticancer
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8 K. Chouaı¨b et al.6.5.1. (1-phenyl-1H-1,2,3-triazol-4-yl)methyl-(3b)-3-
hydroxyolean-12-en-28-oate (6a)
Yellow paste; yield 94% (0.115 g), mp: 222–224 C; 1H NMR
(300 MHz, CDCl3): d 8.01 (1H, s), 7.70 (2H, dd, J= 7.5;
1.5 Hz), 7.50 (2H, dd, J= 7.2; 1.5 Hz), 7.42 (1H, m), 5.25
(3H, m), 3.15 (1H, dd, J= 11.2; 4.8 Hz), 2.87 (1H, dd,
J= 7.7; 3.8 Hz), 1.94 (2H, m), 1.80 (2H, dd, J= 8.7; 3.5
Hz), 1.63–1.45 (12H, m), 1.34 (2H, m), 1.26 (4H, m), 1.08
(3H, s), 0.94 (3H, s), 0.89 (3H, s), 0.86 (3H, s), 0.74 (3H, s),
0.72 (3H, s), 0.44 (3H, s); 13C NMR (75 MHz, CDCl3): d
177.7, 143.7, 143.5, 136.5, 129.7, 129.7, 129.7, 128.8, 122.5,
120.5, 120.5, 78.9, 57.3, 55.2, 47.5, 46.7, 45.8, 41.6, 41.4,
39.2, 38.7, 38.4, 36.9, 33.6, 33.0, 32.6, 32.4, 30.6, 29.6, 28.0,
27.6, 27.1, 25.7, 23.9, 23.8, 22.9, 18.2, 16.7, 15.5, 15.1; HRMS
(ESI+): calcd. for (C39H56N3O3)
+ [M+H]+ 614.4322, found
614.4324.
6.5.2. (1-(4-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methyl-
(3b)-3-hydroxyolean-12-en-28-oate (6b)
Dark purple solid; yield 98% (0.126 g), mp: 220–221 C; 1H
NMR (300 MHz, CDCl3): d 7.96 (1H, s), 7.62 (2H, d,
J= 7.8 Hz), 7.02 (2H, d, J= 8.1 Hz), 5.25 (3H, m), 3.87 (3H,
s), 3.20 (1H, dd, J= 10.2; 4.2 Hz), 2.84 (1H, dd, J= 8.7;
3.8 Hz), 2.00 (2H, m), 1.80 (2H, dd, J= 9.0; 3.0 Hz), 1.63–
1.45 (10H, m), 1.33–1.19 (8H, m), 1.10 (3H, s), 0.97 (3H, s),
0.91 (3H, s), 0.89 (3H, s), 0.78 (3H, s), 0.75 (3H, s), 0.46 (3H,
s); 13C NMR (75 MHz, CDCl3): d 177.3, 159.3, 143.1, 143.0,
129.8, 122.2, 122.9, 121.6, 121.6, 114.2, 114.2, 78.4, 56.8, 55.1,
46.9, 46.2, 45.3, 41.1, 40.8, 38.7, 38.2, 37.8, 36.4, 33.2, 32.6,
32.0, 31.8, 30.1, 29.2, 27.6, 27.1, 26.6, 25.2, 23.1, 22.8, 22.4,
17.7, 16.2, 15.0, 14.7; HRMS (ESI+): calcd. for
(C40H58N3O4)
+ [M+H]+ 644.4428, found 644.4416.
6.5.3. (1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methyl-(3b)-
3-hydroxyolean-12-en-28-oate (6c)
Dark red solid; yield 98% (0.127 g), mp: 226–227 C; 1H NMR
(300 MHz, CDCl3): d 8.02 (1H, s), 7.69 (2H, dd, J= 6.9;
2.7 Hz), 7.51 (2H, dd, J= 6.6; 3.0 Hz), 5.28 (3H, m), 3.21
(1H, dd, J= 10.8; 4.2 Hz), 2.87 (1H, dd, J= 9.2; 3.8 Hz),
2.01 (1H, m), 1.80 (2H, dd, J= 7.8; 2.4 Hz), 1.68–1.45 (12H,
m), 1.29 (3H, m), 1.18 (4H, m), 1.11 (3H, s), 0.97 (3H, s),
0.92 (3H, s), 0.90 (3H, s), 0.78 (3H, s), 0.76 (3H, s), 0.46
(3H, s); 13C NMR (75 MHz, CDCl3): d 177.8, 143.5, 135.5,
134.6, 129.9, 129.9, 129.0, 122.5, 121.6, 121.6, 116.2, 78.9,
57.2, 55.1, 47.5, 46.7, 45.8, 41.6, 41.3, 39.2, 38.7, 38.4, 36.9,
33.8, 33.0, 32.6, 32.4, 31.8, 30.6, 28.0, 27.6, 27.1, 25.7, 23.6,
23.3, 22.9, 18.2, 16.7, 15.5; HRMS (ESI+): calcd. for
(C39H55ClN3O3)
+ [M+H]+ 648.3932, found 648.3924.
6.5.4. (1-(4-bromophenyl)-1H-1,2,3-triazol-4-yl)methyl-(3b)-
3-hydroxyolean-12-en-28-oate (6d)
White solid; yield 96% (0.132 g), mp: 214–216 C; 1H NMR
(300 MHz, CDCl3): d 8.01 (1H, s), 7.65 (2H, dd, J= 8.1;
3.4 Hz), 7.50 (2H, dd, J= 7.8; 3.2 Hz), 5.29 (3H, m), 3.21
(1H, dd, J= 10.8; 4.2 Hz), 2.87 (1H, dd, J= 9.2; 3.8 Hz),
1.99 (2H, m), 1.80 (2H, dd, J= 7.9; 2.8 Hz), 1.71–1.55 (10H,
m), 1.33–1.27 (4H, m), 1.18 (4H, m), 1.11 (3H, s), 0.97 (3H,
s), 0.92 (3H, s), 0.90 (3H, s), 0.78 (3H, s), 0.76 (3H, s), 0.46
(3H, s); 13C NMR (75 MHz, CDCl3): d 177.9, 143.7, 136.1,
133.9, 129.2, 129.2, 129.0, 122.5, 120.8, 120.8, 115.9, 78.7,Please cite this article in press as: Chouaı¨b, K. et al., Regiospecific synthesis by copp
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33.9, 33.3, 32.9, 32.4, 31.8, 30.6, 28.7, 27.9, 27.4, 25.7, 23.6,
23.3, 22.9, 18.2, 16.8, 15.2; HRMS (ESI+): calcd. for
(C39H55BrN3O3)
+ [M+H]+ 692. 3427, found 692.3427.
6.5.5. (1-(4-nitrophenyl)-1H-1,2,3-triazol-4-yl)methyl-(3b)-3-
hydroxyolean-12-en-28-oate (6e)
Yellow solid; yield 90% (0.118 g), mp: 218–320 C; 1H NMR
(300 MHz, CDCl3): d 8.02 (1H, s), 7.60 (2H, d, J= 7.9 Hz),
7.00 (2H, d, J= 8.1 Hz), 5.28 (3H, m), 3.23 (1H, dd,
J= 10.8; 3.8 Hz), 2.87 (1H, dd, J= 9.6; 4.0 Hz), 2.01 (1H,
m), 1.83 (2H, dd, J= 7.8; 2.6 Hz), 1.68–1.44 (12H, m), 1.29
(3H, m), 1.22 (4H, m), 1.10 (3H, s), 0.98 (3H, s), 0.92 (3H,
s), 0.90 (3H, s), 0.79 (3H, s), 0.76 (3H, s), 0.49 (3H, s); 13C
NMR (75 MHz, CDCl3): d 177.6, 143.1, 135.0, 134.4, 129.6,
129.6, 129.0, 122.4, 121.4, 121.4, 116.8, 78.9, 56.8, 55.0, 47.2,
46.6, 45.5, 41.3, 41.0, 39.2, 38.7, 38.2, 36.9, 33.8, 33.0, 32.7,
32.4, 31.8, 30.9, 28.2, 27.6, 27.0, 25.7, 23.9, 23.3, 22.9, 18.2,
16.8, 15.9; HRMS (ESI+): calcd. for (C39H55N4O5)
+ [M
+H]+ 659. 4173, found 659.4175.
6.5.6. (1-(3-methylphenyl)-1H-1,2,3-triazol-4-yl)methyl-(3b)-
3-hydroxyolean-12-en-28-oate (6f)
Yellow solid; yield 92% (0.115 g), mp: 231–232 C; 1H NMR
(300 MHz, CDCl3): d 8.02 (1H, s), 7.55 (1H, s), 7.50 (1H, d,
J= 8.1 Hz), 7.39 (1H, t, J= 7.5 Hz), 7.25 (1H, d,
J= 7.5 Hz), 5.28 (3H, m), 3.23 (1H, dd, J= 10.8; 4.2 Hz),
2.87 (1H, dd, J= 9.2; 3.8 Hz), 2.44 (3H, s), 1.95 (1H, td,
J= 10.2; 3.8 Hz), 1.83 (2H, dd, J= 8.7; 3.3 Hz), 1.67–1.43
(10H, m), 1.38 (8H, m), 1.12 (3H, s), 1.04 (3H, s), 0.97 (3H,
s), 0.94 (3H, s), 0.78 (3H, s), 0.75 (3H, s), 0.67 (1H, m), 0.45
(3H, s); 13C NMR (75 MHz, CDCl3): d 177.7, 143.6, 143.5,
139.9, 136.9, 129.5, 129.4, 122.6, 122.4, 121.2, 117.6, 78.9,
57.3, 55.1, 47.5, 46.7, 45.8, 41.6, 41.3, 39.2, 38.7, 38.4, 36.9,
33.8, 33.0, 32.6, 32.4, 31.8, 30.6, 29.6, 28.0, 27.6, 27.1, 25.7,
23.6, 23.3, 22.9, 18.2, 16.7, 15.5; HRMS (ESI+): calcd. for
(C40H58N3O3)
+ [M+H]+ 628. 4478, found 628.4481.
6.5.7. (1-naphthalen-1-yl-1H-1,2,3-triazol-4-yl)methyl-(3b)-3-
hydroxyolean-12-en-28-oate (6g)
Dark red solid; yield 87% (0.115 g), mp: 246–247 C; 1H NMR
(300 MHz, CDCl3): d 8.03–7.94 (3H, m), 7.65–7.50 (5H, m),
5.38 (1H, d, J= 12.9 Hz), 5.30 (1H, d, J= 13.8 Hz), 5.26
(1H, s), 3.17 (1H, dd, J= 10.8; 5.1 Hz), 2.88 (1H, dd,
J= 13.5; 4.2 Hz), 1.94 (1H, m), 1.80 (2H, m), 1.71–1.57 (3H,
m), 1.60–1.47 (8H, m), 1.42–1.37 (2H, m), 1.28–1.19 (6H, m),
1.12 (3H, s), 0.96 (3H, s), 0.91 (3H, s), 0.88 (3H, s), 0.74
(3H, s), 0.73 (3H, s), 0.54 (3H, s); 13C NMR (75 MHz, CDCl3):
d 177.3, 143.1, 142.7, 133.7, 133.0, 129.9, 127.8, 127.8, 127.4,
126.5, 126.2, 124.4, 122.9, 121.9, 121.8, 78.4, 59.8, 57.0, 54.6,
47.0, 46.3, 45.3, 41.2, 40.8, 38.3, 38.2, 37.9, 36.4, 33.3, 32.5,
31.9, 30.1, 27.6, 27.1, 26.6, 25.2, 23.1, 22.8, 22.5, 17.7, 16.5,
15.0, 14.6; HRMS (ESI+): calcd. for (C43H58N3O3)
+ [M
+H]+ 664. 4478, found 664.4476.
6.6. General procedure for the synthesis of compounds 7a–g: Ru-
catalyzed azide–alkyne cycloaddition
To a solution of alkyne 5 (0.1 g, 0.2 mmol) in DMF, Cp*RuCl
(PPh3)2 (5 mol%) was added at room temperature. To thiser- and ruthenium-catalyzed azide–alkyne 1,3-dipolar cycloaddition, anticancer
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mixture was subjected to microwave irradiations at 250 W
completed within 3–6 min. The crude mixture was extracted
with EtOAc (3  25 mL) and the combined organic layer
was dried over sodium sulfate, concentrated in vacuo and puri-
fied through a column chromatography or recrystallization, to
give pure 7a–g in 84–96% yields.6.6.1. (1-phenyl-1H-1,2,3-triazol-5-yl)methyl-(3b)-3-
hydroxyolean-12-en-28-oate (7a)
Gummy yellowish; yield 90% (0.110 g), mp: 288–289 C; 1H
NMR (300 MHz, CDCl3/CD3OD): d 8.17 (1H, s), 7.93–7.85
(5H, m), 5.53 (1H, t, J= 3.6 Hz), 5.50 (1H, d,
J= 13.5 Hz), 5.41 (1H, d, J= 13.5 Hz), 3.45 (1H, t,
J= 6.3 Hz), 3.11 (1H, dd, J= 11.8; 3.8 Hz), 2.14 (2H, m),
1.93–1.85 (8H, m), 1.77–1.65 (8H, m), 1.59 (2H, m), 1.52
(2H, m), 1.42 (3H, s), 1.27 (3H, s), 1.20 (6H, s), 1.17 (3H,
s), 1.06 (3H, s), 0.81 (3H, s); 13C NMR (75 MHz, CDCl3/
CD3OD): d 180.6, 146.7 139.1, 138.6, 136.4, 133.5, 133.1,
133.1, 128.1, 128.1, 126.2, 81.9, 58.6, 57.0, 52.4, 51.6, 49.1,
45.0, 44.7, 42.6, 42.0, 39.2, 38.7, 38.4, 41.9, 40.3, 37.0, 36.1,
33.4, 31.7, 31.4, 30.5, 29.5, 27.1, 26.9, 22.1, 20.5, 19.3, 18.7;
HRMS (ESI+): calcd. for (C39H56N3O3)
+ [M+H]+
614.4321, found 614.4304.6.6.2. (1-(4-methoxyphenyl)-1H-1,2,3-triazol-5-yl)methyl-
(3b)-3-hydroxyolean-12-en-28-oate (7b)
Dark red solid; yield 96% (0.123 g), mp: 292–294 C; 1H NMR
(300 MHz, CDCl3): d 7.82 (1H, s), 7.47 (2H, dd, J= 6.9;
2.1 Hz), 7.05 (2H, dd, J= 6.9; 2.1 Hz), 5.27 (1H, t,
J= 3.1 Hz), 5.11 (1H, d, J= 13.5 Hz), 5.06 (1H, d,
J= 13.8 Hz), 3.89 (3H, s), 3.21 (1H, dd, J= 10.8; 4.0 Hz),
2.84 (1H, dd, J= 8.8; 3.4 Hz), 2.01 (1H, m), 1.80 (2H, dd,
J= 8.7; 3.6 Hz), 1.66–1.45 (16H, m), 1.32 (3H, s), 1.10 (3H,
s), 1.12 (3H, s), 0.99 (3H, s), 0.91 (3H, s), 0.88 (3H, s), 0.78
(3H, s), 0.56 (3H, s); 13C NMR (75 MHz, CDCl3): d 176.3,
160.1, 142.8, 134.7, 132.3, 128.3, 125.7, 125.7, 122.2, 114.2,
114.2, 78.4, 55.1, 54.7, 53.3, 47.0, 46.4, 45.2, 41.2, 40.8, 38.7,
38.2, 37.9, 36.5, 33.2, 32.4, 32.1, 31.8, 30.1, 27.6, 27.1, 26.6,
25.3, 23.0, 22.8, 22.6, 17.7, 16.3, 15.0, 14.8; HRMS (ESI+):
calcd. for (C40H58N3O4)
+ [M+H]+ 644.4427, found
644.4407.6.6.3. (1-(4-chlorophenyl)-1H-1,2,3-triazol-5-yl)methyl-(3b)-
3-hydroxyolean-12-en-28-oate (7c)
Dark red solid; yield 94% (0.121 g), mp: 284–286 C; 1H NMR
(300 MHz, CDCl3): d 7.85 (1H, s), 7.58–7.50 (4H, m), 5.26
(1H, t, J= 3.3 Hz), 5.16 (1H, d, J= 13.5 Hz), 5.08 (1H, d,
J= 13.5 Hz), 3.23 (1H, dd, J= 10.2; 4.0 Hz), 2.84 (1H, dd,
J= 11.2; 3.8 Hz), 2.04 (2H, m), 1.80 (2H, dd, J= 8.2;
3.1 Hz), 1.64–1.35 (18H, m), 1.16 (3H, s), 0.99 (3H, s), 0.91
(3H, s), 0.89 (3H, s), 0.88 (3H, s), 0.81 (3H, s), 0.53 (3H, s);
13C NMR (75 MHz, CDCl3): d 176.8, 143.3, 135.9, 135.7,
134.4, 132.4, 129.9, 129.9, 125.9, 125.9, 122.8, 78.9, 55.2,
53.5, 47.5, 46.9, 45.7, 41.7, 41.3, 39.2, 38.7, 38.4, 37.0, 33.7,
32.9, 32.6, 32.3, 30.6, 29.6, 28.0, 27.5, 27.1, 25.8, 23.5, 23.3,
23.1, 18.2, 16.7, 15.5; HRMS (ESI+): calcd. for (C39H55ClN3-
O3)
+ [M+H]+ 648.3932, found 648.3915.Please cite this article in press as: Chouaı¨b, K. et al., Regiospecific synthesis by copp
and anti-inflammatory activities of oleanolic acid triazole derivatives. Arabian Journ6.6.4. (1-(4-bromophenyl)-1H-1,2,3-triazol-5-yl)methyl-(3b)-
3-hydroxyolean-12-en-28-oate (7d)
White solid; yield 92% (0.127 g), mp: 286–287 C; 1H NMR
(300 MHz, CDCl3): d 7.82 (1H, s), 7.42 (2H, dd, J= 7.2;
2.6 Hz), 7.08 (2H, dd, J= 7.2; 2.4 Hz), 5.27 (1H, t,
J= 3.1 Hz), 5.18 (1H, d, J= 13.5 Hz), 5.10 (1H, d,
J= 13.5 Hz), 3.21 (1H, dd, J= 10.8; 4.2 Hz), 2.86 (1H, dd,
J= 9.2; 3.8 Hz), 2.01 (2H, m), 1.80 (2H, dd, J= 7.9;
2.6 Hz), 1.69–1.39 (12H, m), 1.31 (2H, m), 1.18 (4H, m), 1.11
(3H, s), 0.99 (3H, s), 0.95 (3H, s), 0.93 (3H, s), 0.78 (3H, s),
0.76 (3H, s), 0.54 (3H, s); 13C NMR (75 MHz, CDCl3): d
178.2, 144.7, 136.1, 133.9, 129.8, 129.8, 129.0, 122.5, 120.4,
120.4, 116.5, 78.6, 56.7, 55.4, 47.6, 46.7, 45.2, 41.9, 41.3,
39.4, 38.7, 38.8, 36.7, 33.9, 33.3, 32.9, 32.4, 31.8, 30.6, 28.7,
27.9, 27.7, 25.7, 23.6, 23.3, 22.9, 18.2, 16.9, 15.8; HRMS
(ESI+): calcd. for (C39H55BrN3O3)
+ [M+H]+ 692.3427,
found 692.3420.
6.6.5. (1-(4-nitrophenyl)-1H-1,2,3-triazol-5-yl)methyl-(3b)-3-
hydroxyolean-12-en-28-oate (7e)
Yellow solid; yield 96% (0.126 g), mp: 294–296 C; 1H NMR
(300 MHz, CDCl3): d 7.82 (1H, s), 7.49 (2H, dd, J= 6.9;
2.1 Hz), 7.11 (2H, dd, J= 6.9; 2.1 Hz), 5.27 (1H, t,
J= 3.3 Hz), 5.08 (2H, m), 3.23 (1H, dd, J= 10.8; 4.0 Hz),
2.86 (1H, dd, J= 8.8; 3.4 Hz), 2.01 (2H, m), 1.80 (2H, dd,
J= 8.7; 3.6 Hz), 1.60–1.45 (12H, m), 1.40 (4H, m), 1.32 (2H,
s), 1.10 (3H, s), 1.12 (3H, s), 0.99 (3H, s), 0.91 (3H, s), 0.88
(3H, s), 0.78 (3H, s), 0.56 (3H, s); 13C NMR (75 MHz, CDCl3):
d 177.3, 159.8, 142.6, 134.7, 132.3, 128.3, 125.9, 125.9, 122.2,
116.2, 116.2, 78.4, 55.1, 54.7, 47.0, 46.4, 45.2, 41.2, 40.8,
38.7, 38.2, 37.9, 36.5, 33.2, 32.4, 32.1, 31.8, 30.1, 27.6, 27.1,
26.6, 25.3, 23.5, 22.8, 22.6, 17.9, 16.6, 15.9, 15.5; HRMS
(ESI+): calcd. for (C39H55N4O5)
+ [M+H]+ 659.4172, found
659.4163.
6.6.6. (1-(3-methylphenyl)-1H-1,2,3-triazol-5-yl)methyl-(3b)-
3-hydroxyolean-12-en-28-oate (7f)
Dark red solid; yield 92% (0.115 g), mp: 296–297 C; 1H NMR
(300 MHz, CDCl3): d 7.84 (1H, s), 7.41–7.26 (4H, m), 5.27
(1H, t, J= 3.3 Hz), 5.15 (1H, d, J= 13.5 Hz), 5.10 (1H, d,
J= 13.5 Hz), 3.21 (1H, dd, J= 10.8; 4.2 Hz), 2.84 (1H, dd,
J= 9.2; 3.8 Hz), 2.46 (3H, s), 2.00 (2H, m), 1.85 (2H, dd,
J= 8.7; 3.3 Hz), 1.74–1.42 (13H, m), 1.38 (4H, m), 1.12 (3H,
s), 0.99 (3H, s), 0.91 (3H, s), 0.91 (3H, s), 0.88 (3H, s), 0.78
(3H, s), 0.71 (1H, m), 0.56 (3H, s); 13C NMR (75 MHz,
CDCl3): d 176.8, 143.3, 139.9, 135.8, 132.4, 130.5, 129.9,
129.7, 129.2, 122.7, 121.7, 78.9, 55.2, 53.8, 47.5, 46.7, 45.8,
41.6, 41.3, 39.2, 38.7, 38.4, 36.9, 33.8, 33.0, 32.6, 32.4, 31.8,
30.6, 29.6, 28.0, 27.6, 27.1, 25.7, 23.6, 23.3, 22.9, 18.2, 16.7,
15.5; HRMS (ESI+): calcd. for (C40H58N3O3)
+ [M+H]+
628.4478, found 628.4502.
6.6.7. (1-naphthalen-1-yl-1H-1,2,3-triazol-5-yl)methyl-(3b)-3-
hydroxyolean-12-en-28-oate (7g)
Dark red solid; yield 84% (0.111 g), mp: 295–297 C; 1H NMR
(300 MHz, CDCl3): d 8.08 (1H, d, J= 7.6 Hz), 7.99 (1H, d,
J= 7.8 Hz), 7.96 (1H, s), 7.65–7.50 (4H, m), 7.22 (1H, d,
J= 8.4 Hz), 5.17 (1H, s), 4.99 (1H, d, J= 13.4 Hz), 4.29
(1H, d, J= 13.8 Hz), 3.22 (1H, dd, J= 10.8; 5.4 Hz), 2.73er- and ruthenium-catalyzed azide–alkyne 1,3-dipolar cycloaddition, anticancer
al of Chemistry (2016), http://dx.doi.org/10.1016/j.arabjc.2015.12.013
10 K. Chouaı¨b et al.(1H, dd, J= 13.5; 4.2 Hz), 1.83 (3H, m), 1.71–1.42 (11H, m),
1.42–1.35 (6H, m), 1.28–1.19 (2H, m), 1.27 (3H, s), 1.06 (3H,
s), 0.98 (3H, s), 0.90 (3H, s), 0.85 (3H, s), 0.80 (3H, s), 0.48
(3H, s); 13C NMR (75 MHz, CDCl3): d 177.3, 143.1, 142.7,
133.7, 133.0, 129.9, 127.8, 127.8, 127.4, 126.5, 126.2, 124.4,
122.9, 121.9, 121.8, 78.4, 59.8, 57.0, 54.6, 47.0, 46.3, 45.3,
41.2, 40.8, 38.3, 38.2, 37.9, 36.4, 33.3, 32.5, 31.9, 30.1, 27.6,
27.1, 26.6, 25.2, 23.1, 22.8, 22.5, 17.7, 16.5, 15.0, 14.6; HRMS
(ESI+): calcd. for (C43H58N3O3)
+ [M+H]+ 664.4478, found
664.4482.
6.7. Biological assay
Natural pentacyclic triterpenoid (Oleanolic acid 1) and most of
the synthesized triazoles type 6 and 7 were dissolved in
dimethyl sulfoxide (DMSO) and added into the medium at
final concentrations of 10, 30 and 100 lM. The final concentra-
tion of DMSO was 0.33% and was determined to have no
cytotoxicity.
6.7.1. Determination of anticancer activity in EMT-6 and
SW480 cancer cell lines
Murine mammary carcinoma cell line EMT-6 and human col-
orectal adenocarcinoma cell line SW480, purchased from
American Type Culture Collection (ATCC, Manassas, VA),
were cultured in DMEM supplemented with 10% of fetal
bovine serum and penicillin (100 U/mL), streptomycin
(100 lg/mL), and amphotericin B (250 ng/mL) and placed in
CO2 incubator with 5% of CO2 at 37 C. Cells were seeded in
a 96-well microplate at 3.125  104 cells/mL and treated with
compounds for 48 h. Doxorubicin, etoposide, 5-fluorouracil
and methotrexate (10 lM) were used as anticancer references.
The anticancer activity of compounds and drug references
was determined using XTT assay (Jost et al., 1992; Manase
et al., 2014). This assay is based on the conversion of the
water-soluble XTT (sodium 2,3,-bis(2-methoxy-4-nitro-5-sulfo
phenyl)-5-[(phenylamino)-carbonyl]-2H-tetrazolium) inner
salt) reagent, in the presence of the electron coupling reagent
PMS (phenazine methylsulfate) to an orange formazan product
by metabolically active cells. The amount of formazan pro-
duced was detected by the measurement of the absorbance at
499 nm and a reference wavelength was used at 660 nm on a
microplate reader Infinite M200 Pro TECAN. Cell viability is
expressed as a percentage of control, which was taken as 100%.
6.7.2. Determination of pro-inflammatory IL-1b cytokine
production in PBMCs
Human peripheral blood mononuclear cells (PBMCs) were
isolated from buffy coats from healthy donors by density
gradient centrifugation (Pancoll human, d.1.077 g/mL).
Recovered PBMCs were washed three times in Dulbecco’s
phosphate buffered saline, seeded in a 96-well microplate at
6.67  105 cells/mL in RPMI-1640 containing 10% fetal
bovine serum, penicillin (100 U/mL), streptomycin (100 lg/
mL), amphotericin B (250 ng/mL), and incubated at 5% CO2
and 37 C. PBMCs were treated with compounds (10, 30,
100 lM) and then were stimulated for 24 h with LPS
(Escherichia coli, 0128:B12, Sigma) (10 ng/mL) (Schindler
et al., 1990; Shah et al., 2010). Three anti-inflammatory refer-
ences were tested in the same conditions: ZVAD (5 lM), dex-
amethasone (DEXA, 1 lM) and prednisolone (PRED,Please cite this article in press as: Chouaı¨b, K. et al., Regiospecific synthesis by copp
and anti-inflammatory activities of oleanolic acid triazole derivatives. Arabian Journ70 lM). After incubation, the supernatants were harvested
and kept at 20 C until use. Viability of PBMCs was assessed
by XTT assay. Secretion IL-1b was measured only in the cul-
ture supernatants of PBMCs treated with compounds that
showed low toxicity, using a sandwich enzyme-linked
immunosorbent assay (ELISA) method (eBioscience, San
Diego, USA), according to manufacturer instructions.
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